Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODI

Affiliation auteurs!!!! Error affiliation !!!!
TitreBevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODI
Type de publicationJournal Article
Year of Publication2017
AuteursBennouna J., Hiret S., Borg C., Bertaut A., Bouche O., Deplanque G., Francois E., Conroy T., Ghiringhelli F., G. Guetz D, Seitz J-F., Artru P., Stanbury T., Charpentier S., Denis M., Adenis A.
JournalANNALS OF ONCOLOGY
Volume28
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534